Dr. Mike Aitkenhead

In a report published Thursday, Edison Investment Research analyst Dr. Mike Aitkenhead commented on recent developments related to CytRx Corporation (NASDAQ: CYTR). In the report, Edison Investment Research noted, “Following positive aldoxorubicin data in soft tissue sarcoma (STS) and glioblastoma...

In a report published Wednesday, Edison Investment Research analyst Dr. Mike Aitkenhead commented on recent developments related to Threshold Pharmaceuticals (NASDAQ: THLD). In the report, Edison Investment Research noted, “Threshold has amended the protocol of its ongoing TH-302 Phase III study...